232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Hanna, Daire; Merrick, Sophie; Ghose, Abhimanyu; Yang, Dongyun; Phillips, E.; Chopra, N.R.; Ross, Kendra; Boh, Z.; Swampillai, Angela; Robinson, T.M.; Germain, Lucie; Atkinson, Carol; Konstantis, Apostolos; Riddle, Pippa; Cresti, Nicola; Naik, Jay; Borley, Annabel; Guppy, Amy; Schmid, Peter; Phillips, Melissa

doi:10.1016/j.esmoop.2023.101420

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature review of published data resulted in five publications, including one abstract on real-world experience with SG [15], three clinical case reports [16][17][18], and one single-center case series [19] [Figure 1].…”

Section: Published Clinical Data On Sacituzumab Govitecan Combined Wi...mentioning

confidence: 99%

“…Hanna et al reported on the treatment of 132 patients with SG; 11 of them received additional radiotherapy because of brain metastases [15]. Importantly, patients who received radiotherapy had superior PFS compared to patients that had no radiotherapy (hazard ratio 0.27, 95% confidence interval (CI) 0.1-0.71, p = 0.006).…”

Section: Published Clinical Data On Sacituzumab Govitecan Combined Wi...mentioning

confidence: 99%

See 1 more Smart Citation

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study

Krug,

Tio,

Abaci

et al. 2024

Cancers

View full text Add to dashboard Cite

Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody–drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases locally. Concurrent use of SG and irradiation was excluded in clinical trials of SG, and there are currently limited published data. We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration.

show abstract

Section: Published Clinical Data On Sacituzumab Govitecan Combined Wi...mentioning

confidence: 99%

Section: Published Clinical Data On Sacituzumab Govitecan Combined Wi...mentioning

confidence: 99%

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study

Krug,

Tio,

Abaci

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Hurvitz,

Bardia,

Punie

et al. 2024

npj Breast Cancer

View full text Add to dashboard Cite

In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients with mTNBC refractory to/relapsing after ≥2 prior chemotherapies (≥1 in the metastatic setting) were randomized 1:1 to receive SG or treatment of physician’s choice (TPC) until unacceptable toxicity/progression. The primary endpoint was progression-free survival (PFS) per RECIST 1.1 by central review in patients without brain metastases. Patients with brain metastases were allowed if metastases were stable ≥4 weeks. In the intention-to-treat (ITT) population, 19% of patients were age ≥65 years; 12% were Black, and 12% had brain metastases. SG improved PFS and overall survival (OS), respectively, vs TPC in patients age ≥65 years (7.1 vs 2.4 months and 14.7 vs 8.9 months), or of Black race (5.4 vs 2.2 months and 13.8 vs 8.5 months), consistent with outcomes in the ITT population. Patients with brain metastases had numerically higher median PFS with SG vs TPC, but median OS was similar between treatment groups. SG was well tolerated and had a manageable safety profile consistent with the full safety population across all subgroups; neutropenia and diarrhea were the most common treatment-emergent adverse events. These findings confirm the meaningful clinical benefit of SG vs standard chemotherapy in patient subgroups with high unmet needs. SG should be considered an effective and safe treatment option for patients with mTNBC eligible for second-line or later therapy. ClinicalTrials.gov Number: NCT02574455.

show abstract

Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Alaklabi,

Roy,

Zagami

et al. 2024

JCO Oncol Pract

View full text Add to dashboard Cite

PURPOSE Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC. METHODS A multi-institution retrospective study of patients with mTNBC treated with SG from January 2021 to May 2023 was conducted. Demographic and clinicopathologic variables were collected. Univariate and multivariate Cox regression models were used for survival analysis. RESULTS A total of 115 patients were included. The median age at SG initiation was 60 years (range, 31-85). All patients were female; 73 (63.5%) were White and 31 (27.0%) were Black. The median number of previous therapies in the metastatic setting was two (range, 0-8). Sixty-one (56.0%) patients had primary refractory disease. Median relative dose intensity was 92% (range, 33%-100%). Grade 3 or higher adverse events (AEs) were seen in 50.9% of patients, which included neutropenia (35.7%), anemia (27.0%), vomiting (16.5%), fatigue (8.7%), and diarrhea (7.0%). Dose reductions and treatment discontinuation due to AEs were required in 51.3% and 13.2%, respectively. The objective response rate (ORR) was 27.8%. Median overall survival was 9.6 months (95% CI, 7.8 to 12.9) and median progression-free survival (PFS) was 4.8 months (95% CI, 3.6 to 5.9). In patients with human epidermal growth factor receptor 2 (HER2)–low mTNBC who received trastuzumab deruxtecan (T-DXd) after SG, the ORR to T-DXd was 34.8% and median PFS was 7 months (95% CI, 4.6 to 10.1). CONCLUSION In a real-world cohort of heavily pretreated patients with mTNBC, SG retains its clinical activity. In a subgroup with HER2-low disease, T-DXd continues to demonstrate promising clinical activity after SG, supporting the use of sequential antibody-drug conjugates in this population.

show abstract

232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Cited by 3 publications

References 0 publications

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Contact Info

Product

Resources

About